Abstract

Brain cancer is characterised by many different clinical phenotypes whose common feature is the rapid evolution of treatment-resistant disease. Insights into the molecular and genetic basis for these phenomena will come from a greater understanding of the clonal and genetic diversity both between patients (inter-tumour heterogeneity) and within patients (intra-tumour heterogeneity). Parallel advances in ‘imaging the genome’ are beginning to provide quantitative data that report functional changes in disease biology. This session will review the spectrum of genetic changes in glioblastoma, the commonest adult cancer, and explore how Integrating advanced molecular imaging with high-resolution genomic data will play an increasing role in determining clinical management. Learning objectives:

1. Participants will understanding the current status of genomic analysis of brain cancer.
2. Participants will be able to understand and engage with clinical and translational research.